profit from every €100 of sales.
€0€100
Novozymes
€62.70+3.36% today
+15.8% since Dec 21, 25
1-year low €46.771-year high €64.76
Trading close to its highest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
You pay €50.09 for every €1 of profit it makes in a year.
CheapExpensive
It holds more cash than debt.
No debt5 years
Money in, money out
What Novozymes sold, what it kept, and what it did with the cash.
Sales went from €2.36 billion in 2022 to €4.16 billion in 2025, with €584 million of profit last year.
SalesProfit
Novozymes handed back 67% of the cash it generated last year.
€403M
Free cash flow 2025€751M
Bought back its own shares€100M
Paid as dividends€403M
Novozymes vs. similar companies
Novozymes grows the fastest of these 5 and is the most expensive for its profits.
| Company | Profit from €100 of sales | Sales growth a year | Price per €1 of profit |
|---|---|---|---|
| Novozymes | 50.1× · Expensive | ||
 Linde | 35.0× · Expensive | ||
 L'Air Liquide | 35.1× · Expensive | ||
 Ecolab | 41.8× · Expensive | ||
 The Sherwin-Williams | 32.9× · Expensive |
AI analysis
An AI analyst reads Novozymes's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of EUR | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 2,356 | 2,402 | 3,834 | 4,158 | |
| 1,285 | 1,305 | 1,810 | 2,242 | |
| 594 | 611 | 659 | 883 | |
| 821 | 734 | 1,038 | 1,387 | |
| 493 | 406 | 306 | 584 | |
| 1.77 | 1.46 | 0.67 | 1.25 | |
| 54.6% | 54.3% | 47.2% | 53.9% | |
| 25.2% | 25.4% | 17.2% | 21.2% | |
| 20.9% | 16.9% | 8.0% | 14.0% |
Balance sheet
| In millions of EUR | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 3,756 | 3,809 | 15,196 | 16,349 |
| Cash | 140 | 150 | 280 | 275 |
| Total debt | 919 | 1,039 | 1,797 | – |
| Total liabilities | 1,846 | 1,884 | 4,020 | 5,494 |
| 1,857 | 1,876 | 11,176 | 10,855 | |
| 279 | 278 | 460 | 468 | |
| 15.8% | 13.2% | 2.7% | 5.2% | |
| 26.6% | 21.6% | 2.7% | 5.4% |
Cash flow
| In millions of EUR | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 538 | 557 | 1,020 | 1,222 | |
| 388 | 276 | 360 | 471 | |
| 150 | 281 | 660 | 751 | |
| Dividends paid | 205 | 383 | 250 | 403 |
| 67 | 0 | 0 | 100 | |
| 17 | 20 | 29 | 20 |
Valuation
- 50.1×
- –
- –
- 2.2×
- 7.0×
- 38.9×
- 20.9×
- 2.6%
- 2.0%
- 1.4%
Profitability
- 53.9%
- 21.2%
- 14.0%
- –
- 5.2%
- 9.2%
- –
- –
- –
- –
Growth
- +20.8%
- −11.0%
- –
- –
- +18.8%
Financial health
- -0.2×
- –
- –
- 11.9×
- 0.72
- –
- –
How it ranks in Materials
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 42%of 990
Top 23%of 950
Bottom 16%of 765
Top 17%of 929
Top 48%of 987
1.4%of the share price, paid each year
On $1,000 invested$14a year at today's yield, before tax
–per share
Raised–not every year
How safe it looks
69.0% of its profit
Room to growStretchedMore than it earns: 53.6%
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/7Passes 0 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
48No pass
Benjamin Graham
31No pass
Philip Fisher
45No pass
Peter Lynch
39No pass
Joel Greenblatt
5No pass
Charlie Munger
42No pass
Terry Smith
45No pass
Questions about Novozymes
Is Novozymes a good stock to buy?
A solid business, but the price is high. 0 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Novozymes AI analysis
What does Novozymes do?
Novozymes A/S produces and sells industrial enzymes, functional proteins, and microorganisms in Denmark, rest of Europe, North America, the Asia Pacific, the Middle East, Africa, and Latin America. It is in Specialty Chemicals, based in Lyngby, Denmark, with 10,933 employees.
Does Novozymes pay a dividend?
Yes. At today's price the dividend is 1.4% a year, about 69% of its yearly profit. In 2025 it paid out €403 million in dividends.
Who are Novozymes's competitors?
The largest listed companies in the same industry are Linde, L'Air Liquide, Ecolab and The Sherwin-Williams. The peers table on this page compares their profit, growth and price with Novozymes's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.